AzTrials
AzTrials

GastroparesisPhase 2NCT02970968

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

A Phase 2 study testing VLY-686 (Tradipitant) in people with Gastroparesis, run by Vanda Pharmaceuticals at 38 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Gastroparesis
What is being tested?
VLY-686 (Tradipitant)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
152 participants
Where
38 sitesUnited States
Study dates
Nov 2016to Dec 2018
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed with gastroparesis;
  • Subjects must agree to the use of contraception
  • Ability and acceptance to provide written informed consent;
  • Willing to participate in the pharmacogenomics sample collection;
  • Willing and able to comply with all study requirements and restrictions
  • Willing to not participate in any other interventional trial for the duration of their participation.

Who cannot join

  • Another active disorder or treatment which could explain or contribute to symptoms in the opinion of the Investigator (including but not limited to gastric malignancy, neurological disorder, or heavy doses of strong anticholinergics);
  • Pregnancy or nursing;
  • History of intolerance and/or hypersensitivity to medications similar to VLY-686 (Tradipitant) and its accompanying excipients;
  • Use of another NK1 antagonist or palonosetron;
  • Exposure to any investigational medication, including placebo, within 60 days of the Baseline Visit;
  • Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance, or may confound study results.

Trial locations and contacts

38 sites in 1 country.

38 sites in 1 country

United States38 sites
  • Vanda Investigational Site

    Athens, Georgia, 30607

  • Vanda Investigational Site

    Boston, Massachusetts, 02114

  • Vanda Investigational Site

    Boston, Massachusetts, 02215

  • Vanda Investigational Site

    Chattanooga, Tennessee, 37421

  • Vanda Investigational Site

    Chevy Chase, Maryland, 20815

  • Vanda Investigational Site

    Chula Vista, California, 91910

  • Vanda Investigational Site

    Dothan, Alabama, 36305

  • Vanda Investigational Site

    El Paso, Texas, 79905

  • Vanda Investigational Site

    Elgin, Illinois, 60123

  • Vanda Investigational Site

    Great Neck, New York, 11023

  • Vanda Investigational Site

    Houston, Texas, 77030

  • Vanda Investigational Site

    Huber Heights, Ohio, 45424

  • Vanda Investigational Site

    Huntsville, Alabama, 35801

  • Vanda Investigational Site

    Indianapolis, Indiana, 46202

  • Vanda Investigational Site

    Jackson, Tennessee, 38305

  • Vanda Investigational Site

    Jacksonville, Florida, 32256

  • Vanda Investigational Site

    Largo, Florida, 33777

  • Vanda Investigational Site

    Little Rock, Arkansas, 72211

  • Vanda Investigational Site

    Los Angeles, California, 90095

  • Vanda Investigational Site

    Louisville, Kentucky, 40202

  • Vanda Investigational Site

    Marrero, Louisiana, 70072

  • Vanda Investigational Site

    Mentor, Ohio, 44060

  • Vanda Investigational Site

    Miami, Florida, 33134

  • Vanda Investigational Site

    Minneapolis, Minnesota, 55114

  • Vanda Investigational Site

    Nashville, Tennessee, 37211

  • Vanda Investigational Site

    New York, New York, 10028

  • Vanda Investigational Site

    Norfolk, Virginia, 23502

  • Vanda Investigational Site

    Palo Alto, California, 94305

  • Vanda Investigational Site

    Pascagoula, Mississippi, 39564

  • Vanda Investigational Site

    Philadelphia, Pennsylvania, 19140

  • Vanda Investigational Site

    Raleigh, North Carolina, 27612

  • Vanda Investigational Site

    Richardson, Texas, 75082

  • Vanda Investigational Site

    Salisbury, North Carolina, 28144

  • Vanda Investigational Site

    San Francisco, California, 94115

  • Vanda Investigational Site

    St Louis, Missouri, 63104

  • Vanda Investigational Site

    Tucson, Arizona, 85712

  • Vanda Investigational Site

    Tulsa, Oklahoma, 74104

  • Vanda Investigational Site

    Wyoming, Michigan, 49519

Other trials in United States

About this study

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy of VLY-686 (Tradipitant) in Relieving Symptoms of Gastroparesis

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

The study is divided into two phases: the screening phase and the evaluation phase. The screening phase includes a screening visit to evaluate subjects' preliminary eligibility for the study. During the screening phase, subjects will collect diary data for at least 4 weeks. The evaluation phase includes 4 weeks of randomized double-blind treatment.

Conditions
Gastroparesis
Being tested
VLY-686 (Tradipitant), Placebo
Medical subject headings
Gastroparesis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VLY-686 (Tradipitant)Drug

    oral capsule

  • PlaceboOther

    placebo oral

Study groups in NCT02970968
Study groupRoleWhat they receive
Study DrugExperimentalVLY-686 (Tradipitant) oral capsule for 4 weeks.
Receives: Drug: VLY-686 (Tradipitant)
PlaceboPlacebo comparatorPlacebo oral capsule for 4 weeks.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Average Nausea Severity

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the weekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

    Measured: 4 weeks

Secondary outcomes (6)
  1. Weekly % Nausea-Free Days

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as weekly average post value minus baseline value. Baseline is defined as the average of all nonmissing values in the screening phase (4 weeks).

    Measured: 4 weeks

  2. Daily Average Vomiting Frequency, Change From Baseline

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have vomited in the past 24 hours and how many times they vomited in the past 24 hours. Change from baseline in the weekly average of daily vomiting frequency is calculated as the weekly average post value minus baseline value of the daily daily vomiting frequency from the GCSDD. Baseline is defined as the average of all non-missing values in the screening phase (4 weeks). A negative change indicates improvement.

    Measured: 4 weeks

  3. Gastroparesis Cardinal Symptom Index (GCSI), Change From Baseline

    The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

    Measured: 4 weeks

  4. PAGI-SYM, Change From Baseline

    The PAGI-SYM is a patient reported outcome which asks patients to describe the severity of their symptoms over the last two weeks to measure symptom severity for gastroparesis, functional dyspepsia, and gastroesophageal reflux disease. The measure consists of 20 symptom severity items, which cover the following domains: nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, heartburn/regurgitation, and lower abdominal pain. This questionnaire includes the Gastroparesis Cardinal Symptom Index (GCSI). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value= 5 (very severe). PAGI-SYM Total score is constructed as the average of the six symptom sub-scales and a higher score is indicative of greater symptom severity.

    Measured: 4 weeks

  5. CGI-S, Change From Baseline

    The Clinician Global Impression of Severity (CGI-S) is a 7-point scale on which the clinician rates the severity of the patient's gastroparesis at the time of the assessment and refers to the degree of illness at the time of the visit and during the 2 weeks before the visit. The CGI-S is rated on the following 7-point scale: 1: normal, not at all ill; 2: borderline ill: 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

    Measured: 4 weeks

  6. PGI-C

    The Patient Global Impression of Change (PGI-C) is a patient reported questionnaire with a 7-point rating scale where the participant rates his/her own improvement in overall symptoms relative to the baseline assessment. Is is rated as 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. Higher scores indicate a worse outcome.

    Measured: 4 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2016 (estimated)
  2. Study startNov 2016
  3. Primary completionNov 2018
  4. Study completionDec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
152 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02970968
Sponsor's protocol ID
VP-VLY-686-2301
Status last verified
Jul 2024
First submitted
15 Nov 2016
Last updated
6 Aug 2024
Data monitoring committee
No
Individual data sharing
No

Publications

  • Carlin JL, Lieberman VR, Dahal A, Keefe MS, Xiao C, Birznieks G, Abell TL, Lembo A, Parkman HP, Polymeropoulos MH. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. Gastroenterology. 2021 Jan;160(1):76-87.e4. doi: 10.1053/j.gastro.2020.07.029. Epub 2020 Jul 18.

    PubMed 32693185

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing VLY-686 (Tradipitant) in people with Gastroparesis, run by Vanda Pharmaceuticals at 38 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 38 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 6 Aug 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Average Nausea Severity (time frame: 4 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02970968, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in